Novocure: 18 physicians certified to prescribe NovoTTF Therapy in Europe and Israel

NovocureJul 15 2014

Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy. These physicians will now be able to treat recurrent glioblastoma patients using this novel, anti-mitotic therapy on prescription order outside clinical trials.

The following physicians have been certified to treat patients using NovoTTF Therapy:

Austria
Vienna
-Prof. Priv.-Doz. Dr. med. M. Preusser, Ordinationszentrum Döbling

Czech Republic
Prague
-Prof. Dr. med. J. Vymazal, Na Homolce Hospital

England
London
- Prof. Dr. med. C. Lindquist, Cromwell Hospital

France
Lyon
-Prof. J. Honnorat, Hôpital neurologique, Hospices Civils de Lyon
Paris
-Dr. Ahmed Idbaih, Groupe Hospitalier Pitié Salpêtrière

Germany
Düsseldorf
-Prof. Dr. med. F. Ulrich, Neuro-Unit CME Düsseldorf
Duisburg
-Prof. Dr. med. M. Scholz and Prof. Dr. med. S. Petrasch, Klinikum Duisburg/Wedau Kliniken
Hamburg 
-Dr. med. T. Martens and Prof. Dr. med. M. Westphal, Universitätsklinikum Hamburg-Eppendorf
Heidelberg
-Prof. Dr. med. W. Wick, Universitätsklinikum Heidelberg
Kiel
-Prof. Dr. med. H. M. Mehdorn, Universitätsklinikum Schleswig-Holstein 
Regensburg
-Dr. med. C. Doenitz and Prof. Dr. med. A. Brawanski, Universitätsklinikum

Greece
Athens
-Dr. M. Torrens, ChM FRCS, HYGEIA Hospital

Israel
Tel Aviv
-Prof. Zvi Ram, Tel Aviv Medical Center

Switzerland
Lausanne
-Dr. med. A. Hottinger, MD PhD, Centre Hospitalier Universitaire Vaudois 
Zurich
-Prof. Dr. med. R. Stupp, Zurich University Hospital

"We are honored to be working with such world-renowned oncology experts to provide NovoTTF Therapy to recurrent glioblastoma patients," said Peter Melnyk, Chief Commercial Officer of Novocure. "Training leading physicians at these medical centers is the first step in the commercial launch of our product in Europe and Israel."